Category Archives: AIDS 2010 – Vienna

The 18th International AIDS Conference, Vienna.

New PEPFAR Guidance on HIV Prevention Intervention for Injection Drug Users

By on .

The regional HIV/AIDS epidemics in Russia, Eastern Europe and Southeast Asia are concentrated in part among injection drug users (IDU) and their partners. This population is highly stigmatized, making it difficult to successfully launch appropriate prevention campaigns. In an effort to recognize that the use of syringe exchange programs and medication-assisted therapy can help reduce […]

A Profile: The Medicines Patent Pool Initiative

By on .

During IAS 2010 in Vienna, UNITAID’s Ellen ‘t Hoen gave a plenary presentation on the organization’s new Medicines Patent Pool Initiative, a project that began to take shape in 2008. Hoen leads the program, which aims to lower the cost of HIV/AIDS, malaria and tuberculosis drugs by working with pharmaceutical companies to allow generic production […]

Top Five Lessons from Vienna

By on .

Many themes emerged during the 18th International AIDS Conference last week in Vienna. Here is our list of the top five: Universal Access to HIV Treatment and Prevention Remains Elusive Goal From comments by Bill Gates to the many activist demonstrations, a main theme at IAS 2010 was fear over dwindling funds dedicated to the […]

What We’re Reading: Vienna Edition

By on .

In the fight against AIDS, last week was dizzying – and vitally important.  The International AIDS Conference in Vienna prompted the release of studies and data that some say could revolutionize the world’s prevention efforts. Much talked about is a vaginal gel containing tenofovir, which proved successful in preventing HIV in women. This is the […]

Late Breaker: Daily Oral PrEP for HIV-Negative MSM Shows Encouraging Results

By on .

Vienna – The CAPRISA trial results are not the only good news to come out of the International AIDS Conference. At a late breaker session on Friday, Lisa A. Grohskopf from the CDC presented preliminary findings and analysis of the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) used as pre-exposure prophylaxis (PrEP) […]

Starting HIV Treatment Earlier Improves Mortality for Co-infected Patients on TB Treatment

By on .

The following post is by HIVMA Executive Director Andrea Weddle, reporting from the 18th International AIDS Conference in Vienna. In another late breaker session Thursday, French researcher Blanc presented data supporting early initiation of HIV treatment for patients co-infected with HIV/TB and suggesting it could reduce deaths in co-infected patients by 33 percent. The results […]

Treating Infants with HIV Earlier Saves Money

By on .

The following post is by HIVMA Executive Director Andrea Weddle. She is on location in Vienna, reporting from the 18th International AIDS Conference. South African researcher Meyer-Rath presented compelling data on the cost effectiveness of treating infants early in South Africa at an IAS 2010 late breaker session on Thursday. The findings were based on […]

Lack of TB Screening for PLHA: “Malpractice on the grandest scale”

By on .

Vienna — “Today, only 4.1 percent of people living with HIV/AIDS are screened for TB,” said RESULTS Executive Director Joanne Carter during a press conference Wednesday at IAS 2010.  “And this is despite TB being the most likely infection to kill [HIV infected persons.]” “Failure to provide this screening is malpractice on the grandest scale,” […]

When to Start in Uganda

By on .

The following post is by HIVMA Executive Director Andrea Weddle, reporting from the International AIDS Conference in Vienna. “There’s no separate science for the rich and poor. The research applies to both,” said Dr. Peter Mugyenyi when asked whether “when to start to HIV treatment” was a real question for Uganda and countries in sub-Saharan […]